Sonoco To Report Second Quarter 2025 Results
Globenewswire· 2025-07-01 11:30
Company Overview - Sonoco Products Company is a global leader in high-value sustainable packaging, founded in 1899 [4] - The company operates in 285 locations across 40 countries, employing approximately 23,400 people [4] - Sonoco focuses on value-added, sustainable metal and fiber consumer and industrial packaging [4] - The company was recognized as one of America's Most Trustworthy and Responsible Companies by Newsweek in 2025 [4] Upcoming Earnings Announcement - Sonoco will announce its second quarter 2025 results on July 23, 2025, after market close [1] - A conference call to discuss these results is scheduled for July 24, 2025, at 9:00 a.m. Eastern Time [1][3] - A live audio webcast of the call will be available on the Sonoco Investor Relations website, with a replay accessible for at least 30 days [2]
FinWise Bancorp to Host Second Quarter 2025 Earnings Conference Call and Webcast on Thursday, July 24, 2025
Globenewswire· 2025-07-01 11:30
MURRAY, Utah, July 01, 2025 (GLOBE NEWSWIRE) -- FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), the parent company of FinWise Bank, today announced that it will report its second quarter 2025 results and host a conference call and webcast after the market close on Thursday, July 24, 2025. Conference Call Information The conference call will be held at 5:00 p.m. ET to discuss financial results for the second quarter of 2025. The dial-in number is 1-877-423-9813 (toll-free) or 1-201-689-8573 (int ...
Digi Power X Reports 45% Month-Over-Month Increase in Cash and Crypto Position with no Long-Term Debt and Reports June 2025 Production Results
Globenewswire· 2025-07-01 11:30
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025 MIAMI, July 01, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company that develops data centers, is pleased to provide unaudited comparative Bitcoin (“BTC”) production results for the quarter and month ended June 30, 2025, c ...
Nexxen Announces June 2025 Share Repurchase Program Summary
Globenewswire· 2025-07-01 11:30
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced that during June 2025 the Company repurchased 800,000 Ordinary Shares at an average price of $10.45. As of June 30, 2025, Nexxen had 58,941,174 Ordinary Shares outstanding (excluding treasury shares) and approximately $16.4 million remaining under its current share repurchase program a ...
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Globenewswire· 2025-07-01 11:30
Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royaltiesCLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in blindness. This worldwide, non-exclus ...
Watsco Declares $3.00 Quarterly Dividend
Globenewswire· 2025-07-01 11:30
Marks 200th Consecutive Quarter of Dividend PaymentsMIAMI, July 01, 2025 (GLOBE NEWSWIRE) -- Watsco, Inc.’s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $3.00 on each outstanding share of its Common and Class B common stock payable on July 31, 2025 to shareholders of record at the close of business on July 16, 2025. Watsco has paid dividends to shareholders for 51 consecutive years, with this quarter marking the 200th consecutive quarter of dividend payments. The Company’ ...
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
Globenewswire· 2025-07-01 11:30
SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Adaptive’s clonoSEQ® test for measurable residual disease (MRD) assessment in lymphoid ma ...
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
Globenewswire· 2025-07-01 11:30
PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer’s Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health. Christopher van Dyck, ...
Prospect Capital Corporation Acquires QC Holdings, Inc.
Globenewswire· 2025-07-01 11:00
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (“Prospect”) (NASDAQ: PSEC) has announced the closing of the acquisition of QC Holdings, Inc. (“QC Holdings”), a provider of consumer credit, by Prospect on June 30, 2025. In accordance with the previously announced definitive merger agreement, Prospect has acquired QC Holdings in an all-cash transaction for a total enterprise value of approximately $115 million. The common stock for QC Holdings is no longer listed on a stock exchange. ...
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Globenewswire· 2025-07-01 11:00
– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025 – – Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget – – Common warts affects approxim ...